Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Med Primatol. 2013 Oct;42(5):237-46. doi: 10.1111/jmp.12060.

Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.

Author information

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Abstract

BACKGROUND:

Nonhuman primates (NHPs) are an important model organism for studies of HIV pathogenesis and preclinical evaluation of anti-HIV therapies. The successful translation of NHP-derived data to clinically relevant anti-HIV studies will require better understanding of the viral strains and NHP species used and their responses to existing antiretroviral therapies (ART).

METHODS:

Five pigtailed macaques (Macaca nemestrina) were productively infected with the SIV/HIV chimeric virus SHIV-1157 ipd3N4 following intravenous challenge. After 8 or 27 weeks, ART (PMPA, FTC, raltegravir) was initiated. Viral load, T-cell counts, and production of SHIV-specific antibodies were monitored throughout the course of infection and ART.

RESULTS:

ART led to a rapid and sustained decrease in plasma viral load. Suppression of plasma viremia by ART was independent of the timing of initiation during chronic infection.

CONCLUSIONS:

We present a new NHP model of HIV infection on antiretroviral therapy, which should prove applicable to multiple clinically relevant anti-HIV approaches.

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

KEYWORDS:

HIV; SHIV; antiretroviral therapy; pigtailed macaque; viral reservoir

PMID:
24025078
[PubMed - indexed for MEDLINE]
PMCID:
PMC3772551
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central Icon for Fred Hutchinson Cancer Research Ctr Arnold Library
    Loading ...
    Write to the Help Desk